Effect of bleomycin hydrolase expression in tumor tissue on the therapeutic effectiveness of electrochemotherapyBogataj, Jan (Avtor) Lampreht Tratar, Urša (Avtor) Serša, Gregor (Avtor) Čemažar, Maja (Avtor) Grošelj, Aleš (Avtor) Omerzel, Maša (Avtor) electrochemotherapybleomycin hydrolasepredictive biomarkermurine modelsElectrochemotherapy (ECT) is a cancer treatment that combines application of short electrical pulses with chemotherapy drugs to improve their delivery into tumor cells. Bleomycin is one of the most effective drugs used in ECT, but its success can vary depending on the tumor type. One possible reason is the presence of bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin. In this study, we measured BLMH levels in different mouse tumor cell lines and tumors grown in animals. Thereafter we compared the levels of BLMH with tumor response to ECT and found a correlation with BLMH content, i.e., tumors with higher BLMH content responded poorly. These findings suggest that levels of BLMH could serve as a predictive marker for ECT effectiveness. Testing for BLMH before treatment may help personalize therapy and identify patients most likely to benefit from ECT.MDPI, Basel, Switzerland20252026-04-20 09:53:59Neznano29051UDK: 602ISSN pri članku: 2072-6694DOI: 10.3390/cancers18010127COBISS_ID: 263366147Basel, Switzerlandslby Authors